Yahoo Web Search

  1. Amgen (AMGN) Stock Moves -0.23%: What You Should Know

    Zacks via Yahoo FinanceSep 27 21:50 PM

    In that same time, the Medical sector lost 0.4%, while the S&P 500 gained 3.59%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.63 billion, down 4.63% from ...

  2. This has lagged the Medical sector's loss of 3.82% and the S&P 500's loss of 1.07% in that time. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

  3. Top Ranked Income Stocks to Buy for October 2nd

    Zacks via Yahoo FinanceOct 02 11:34 AM

    Buckle, Inc. (The) Dividend Yield (TTM) Buckle, Inc. (The) dividend-yield-ttm | Buckle, Inc. (The) Quote Amgen Inc. (AMGN): This developer and manufacturer ...

  4. An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12 patients with advanced colorectal cancer who were given the highest dose ...

  5. Meanwhile, Amgen AMGN reported positive data on its leukemia drug from late-stage studies. Positive CHMP Opinion for Regeneron’s Dupixent: Regeneron and partner Sanofi announced that ...

  6. This weekend's Barron's cover story offers 15 roundtable biotech stock picks. Other featured articles discuss the state of the IPO market and dividend-paying value picks. Also, the prospects ...

  7. Pfenex Gets FDA Seal of Approval For Amgen's Forteo Biosimilar

    Benzinga via Yahoo FinanceOct 07 14:36 PM

    Shares of the micro-cap biotech Pfenex Inc (NYSE: PFNX), which pulled back ahead of the PDUFA date for its Forteo biosimilar PF708, were advancing Monday amid a positive outcome for the ...

  8. For the last reported quarter, Amgen came out with earnings of $3.97 per share versus the Zacks Consensus Estimate of $3.58 per share, representing a surprise of 10.89%. With this earnings ...

  9. Pfenex Inc (NYSE: PFNX) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its ...

  10. Options on the $17 billion Health Care Select Sector SPDR Fund, known by its ticker XLV, are particularly attractive, analysts led by John Marshall wrote in a research note. The fund’s implied ...

  1. Ads
    related to Amgen Inc